NR (Nicotinamide Riboside)

Nicotinamide riboside is the NAD precursor with the most paperwork behind it. The EU authorised NR chloride as a novel food in 2020 at up to 300mg a day for adults, and 230mg for those pregnant or breastfeeding, and the FDA had no questions about a 2016 GRAS notice covering it as a source of vitamin B3. That record is about safety, not benefit, and the distinction is the whole point. The pharmacokinetics are settled: single doses of 100, 300 and 1000mg raise the blood NAD metabolome in proportion to the dose, and a four-week trial at 3000mg a day in 20 people with Parkinson's produced no moderate or severe adverse events alongside up to a five-fold rise in blood NAD. What has not been shown is a clinical outcome that follows from any of that. Worth knowing on provenance: the foundational human pharmacokinetic work was funded by the company that sells the ingredient.

Stack Almanac totals your NR against the 300mg a day the EU authorised, which is easy to pass once a NAD blend and a standalone capsule are both in the stack.